-

Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City on Thursday, January 4, 2024. Adam Lenkowsky, executive vice president, chief commercialization officer, will answer questions about the company during a fireside chat at 11 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

For more information, contact:

Media:
media@bms.com

Investors:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
Release Versions
English

Contacts

For more information, contact:

Media:
media@bms.com

Investors:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.......

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference...

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

PRINCETON, N.J.--(BUSINESS WIRE)--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline...
Back to Newsroom